• December 16: The Week in Cancer News

    A second KRAS inhibitor is approved for lung cancer, and a BTK inhibitor challenges standard of care for relapsed or refractory CLL.

    by Marci A. Landsmann

  • December 2: The Week in Cancer News

    Oncologists report that prior authorization process interrupts cancer care, and plant-based diet is associated with lower colorectal cancer risk in men but not women.

    by Eric Fitzsimmons

  • November 4: The Week in Cancer News

    Female patients less likely than men to be told about sexual side effects of treatment, and independent analysis finds cancer-causing chemical in dry shampoo.

    by Marci A. Landsmann

  • October 14: The Week in Cancer News

    Colonoscopy study results are misreported, and progress is seen in cancer vaccines.

    by Kevin McLaughlin

  • October 7: The Week in Cancer News

    Transportation barriers increase risk of death for people with cancer, and new rules go into effect to give patients full access to medical records.

    by Marci A. Landsmann

  • September 23: The Week in Cancer News

    AACR Cancer Progress Report 2022 shows continued decline in cancer death rates, and genetic tests create opportunities but also confusion for breast cancer patients.

    by Eric Fitzsimmons

  • September 16: The Week In Cancer News

    Air pollution research provides clues to how cancer starts, and KRAS-targeting drug appears to keep cancer at bay longer than standard of care, but questions remain

    by Marci A. Landsmann

  • September 9: The Week in Cancer News

    Early-onset cancer is increasing globally, and testing population-wide preventive DNA testing.

    by Kevin McLaughlin

  • September 2: The Week in Cancer News

    Fertility preservation does not impact outcomes for breast cancer patients, and ultraprocessed foods linked to increased risk of colorectal cancer in men.

    by Thomas Celona

  • August 26: The Week in Cancer News

    Advanced cervical cancer rates are rising despite prevention and screening tools, and CAR T-cell therapy inaccessible to many across the country.

    by Eric Fitzsimmons